Janssen Reports Results of Tremfya (guselkumab) in P-III Studies Demonstrated Durable Efficacy Across Joint and Axial Symptoms for Active Psoriatic Arthritis
Shots:
- The P-III (DISCOVER-1 & 2) & (COSMOS) studies evaluate Tremfya in patients with active PsA. The results showed that patients achieved consistent, long-term efficacy @2yrs. across PsA including joint, skin, enthesitis, dactylitis, spinal pain & disease severity EPs. In (DISCOVER-2) study, 40% achieved MDA, 59% DAPSA score of ≤14, & 24% DAPSA ≤4 @100wk.
- The (COSMOS) study showed complete resolution of dactylitis in ≥80% who continued to receive Tremfya @48wk. The safety profile was consistent with that observed in PsO
- The additional analyses showed sustained improvements in measures of HRQoL including fatigue, pain, work productivity & low rates of radiographic progression @2yrs. in biologic-naïve active PsA patients
Ref: Janssen | Image: Janssen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
